Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.51 |
| ▸ | RELA | Q04206 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12071899 | 0.83 | L3MBTL1 (0.57) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL15742312 | 0.83 | NOTUM (0.53) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL7810523 | 0.83 | NOTUM (0.72) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1696225 | 0.83 | NPC1 (0.53) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL21776935 | 0.82 | NOTUM (0.70) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL24988605 | 0.81 | NOTUM (0.51) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL14273303 | 0.81 | NOTUM (0.56) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1545207 | 0.81 | NOTUM (0.51) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL514236 | 0.81 | RAB9A (0.57) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1544834 | 0.81 | NPC1 (0.55) | NOTUMNPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005051380-A1 | SUBSTITUTED UREA-OCTAHYDROINDOLS AS ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR 1 (MCH1R) | BIOVITRUM AB (SE) | 2005-06-09 | — | — | WO | claimed |
| US-11584755-B2 | Dihydrothieno[3,2-b]pyridine compounds | IDEAYA BIOSCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| CN-104685416-B | Photosensitive polymer combination, using its cured film preparation method, cured film, liquid crystal display device and organic EL display device | 富士胶片株式会社 | 2019-05-14 | — | — | CN | disclosed |
| WO-2019067442-A1 | DIHYDROTHIENO[3,2-b]PYRIDINE COMPOUNDS | IDEAYA BIOSCIENCES, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-10240084-B2 | Non-crystallizable pi-conjugated molecular glass mixtures, charge transporting molecular glass mixtures, luminescent molecular glass mixtures, or combinations thereof for organic light emitting diodes and other organic electronics and photonics applications | MOLECULAR GLASSES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-9884832-B2 | Inhibitors targeting drug-resistant influenza A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-06 | — | — | US | disclosed |
| US-20180016275-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2018-01-18 | — | — | US | disclosed |
| CN-104870445-B | New dihydro-pyrimidin and isobioquin group and its pharmaceutical composition (GPR84 antagonists) for treating inflammatory disease | 加拉帕戈斯股份有限公司 | 2017-09-15 | — | — | CN | disclosed |
| US-9708312-B2 | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists) | GALAPAGOS NV (BE) | 2017-07-18 | — | — | US | disclosed |
| EP-2470514-B1 | PSEUDO-DIPEPTIDES AS MMP INHIBITORS | COMMISSARIAT L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-07-12 | — | — | EP | disclosed |
| US-5665719-A | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 1997-09-09 | — | — | US | disclosed |
| EP-0755384-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0714299-A4 | — | — | 1996-07-10 | — | — | EP | disclosed |
| EP-0714299-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-06-05 | — | — | EP | disclosed |
| US-5496833-A | BRONCHODILATOR, ANTIINFLAMMATORY, ANTIARTHRITIC, ANALGESIC, AND ANTIMIGRAINE AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-03-05 | — | — | US | disclosed |
| WO-1995028391-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| US-5444074-A | Treating diseases associated with excess of substance P | MERCK SHARP & DOHME LIMITED (GB) | 1995-08-22 | — | — | US | disclosed |
| WO-1995002405-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1993021181-A1 | AZACYCLIC COMPOUNDS | MERCK SHARP & DOHME LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
| US-4028377-A | PESTICIDES, INSECTICIDES, MITICIDES | CIBA-GEIGY CORPORATION (US) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584755-B2 | Dihydrothieno[3,2-b]pyridine compounds | DHFR, CYC1, CYCS | NOTUM 4542/4885NPC1 889/4885RAB9A 877/4885 |
| US-20180016275-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GPR84, GPR88, GPR65 | NOTUM 4597/4885NPC1 2436/4885RAB9A 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.